Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

Journal of Carcinogenesis

Volumn 3, Issue , 2004, Pages

  Houben, Roland ^a   Becker, Jürgen C ^a   Kappel, Andreas ^b   Terheyden, Patrick ^a   Bröcker, Eva B ^a   Goettz, Rudolf ^a   Rapp, Ulf R ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Nanogen Recognomics GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; RAF PROTEIN; RAS PROTEIN; VALINE;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; EXON; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 2942607408     PISSN: 14773163     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-3163-3-6     Document Type: Article

References (42)

1. Ferlay J, Bray F, Parkin D, Pisani P: Cancer Incidence and Mortality Worldwide. In: IARC Cancer Bases No 5. Lyon: IARCPress; 2001.
2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM et al: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19(16):3622-3634.
3. Schaffer JV, Bolognia JL: The melanocortin-1 receptor: red hair and beyond. Arch Dermatol 2001, 137(11):1477-1485.
4. Halachmi S, Gilchrest BA: Update on genetic events in the pathogenesis of melanoma. Curr Opin Oncol 2001, 13(2):129-136.
5. Pollock PM, Trent JM: The genetics of cutaneous melanoma. Clin Lab Med 2000, 20(4):667-690.
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al: Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
7. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J et al: High frequency of BRAF mutations in nevi. Nat Genet 2003, 33(1):19-20.
8. Naumann U, Eisenmann-Tappe I, Rapp UR: The role of Raf kinases in development and growth of tumors. Recent Results Cancer Res 1997, 143:237-244.
9. Hagemann C, Rapp UR: Isotype-specific functions of Raf kinases. Exp Cell Res 1999, 253(1):34-46.
10. Busca R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychene A, Ortonne JP, Ballotti R: Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. Embo J 2000, 19(12):2900-2910.
11. Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds FH, Jr., Stephenson JR: Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci U S A 1983, 80(14):4218-4222.
12. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63(7):1454-1457.
13. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003, 95(8):625-627.
14. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62(23):6997-7000.
15. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M: Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002, 62(23):7001-7003.
16. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52(5):706-712.
17. Storm SM, Rapp UR: Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 1993, 67(1-3):201-210.
18. Rapp UR, Fensterle J, Albert S, Gotz R: Raf kinases in lung tumor development. Adv Enzyme Regul 2003, 43:183-195.
19. Lang J, Boxer M, MacKie R: Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat 2003, 21(3):327-330.
20. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, Houghton AN, Busam K, Polsky D: Analysis of BRAF and N-RAS Mutations in Metastatic Melanoma Tissues. Cancer Res 2003, 63(14):3955-3957.
21. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA: BRAF Oncogenic Mutations Correlate with Progression rather than Initiation of Human Melanoma. Cancer Res 2003, 63(14):3883-3885.
22. Zhang BH, Guan KL: Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. Embo J 2000, 19(20):5429-5439.
23. Mercer KE, Pritchard CA: Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003, 1653(1):25-40.
24. Fedorov LM, Papadopoulos T, Tyrsin OY, Twardzik T, Gotz R, Rapp UR: Loss of p53 in craf-induced transgenic lung adenoma leads to tumor acceleration and phenotypic switch. Cancer Res 2003, 63(9):2268-2277.
25. Soussi T: The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 2000, 910:121-137; discussion 137-129.
26. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW: Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998, 12(19):3008-3019.
27. Kerkhoff E, Rapp UR: High-intensity Raf signals convert mitotic cell cycling into cellular growth. Cancer Res 1998, 58(8):1636-1640.
28. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET: Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003, 95(12):878-889.
29. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L: ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003, 63(7):1684-1695.
30. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L: Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001, 12(4):863-879.
31. Oft M, Akhurst RJ, Balmain A: Metastasis is driven by sequential elevation of Hras and Smad2 levels. Nat Cell Biol 2002, 4(7):487-494.
32. Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001, 29(2):117-129.
33. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, Hemminki K: BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003, 9(9):3362-3368.
34. Becker JC, Kampgen E, Brocker E: Classical chemotherapy for metastatic melanoma. Clin Exp Dermatol 2000, 25(6):503-508.
35. Smalley KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003, 104(5):527-532.
36. Wu H, Goel V, Haluska FG: PTEN signaling pathways in melanoma. Oncogene 2003, 22(20):3113-3122.
37. Tsao H, Zhang X, Fowlkes K, Haluska FG: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000, 60(7):1800-1804.
38. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P et al: From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 2003, 100(13):7737-7742.
39. Weber CK, Slupsky JR, Herrmann C, Schuler M, Rapp UR, Block C: Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes. Oncogene 2000, 19(2):169-176.
40. Alessi DR, Saito Y, Campbell DG, Cohen P, Sithanandam G, Rapp U, Ashworth A, Marshall CJ, Cowley S: Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. Embo J 1994, 13(7):1610-1619.
41. Robbins DJ, Zhen E, Cheng M, Xu S, Vanderbilt CA, Ebert D, Garcia C, Dang A, Cobb MH: Regulation and properties of extracellular signal-regulated protein kinases 1, 2, and 3. J Am Soc Nephrol 1993, 4(5):1104-1110.
42. Sithanandam G, Kolch W, Duh FM, Rapp UR: Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene 1990, 5(12):1775-1780.